ASCO/EHA/ICML 2021 – Roger Owen
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRoger Owen summarizes the status of emerging therapeutic agents for the treatment of patients with Waldenström’s macroglobulinemia, highlights those that appear most promising, even after failing BTK inhibitors, talks about how to guide treatment decisions, the influence of the mutation profile and expectations of BTK inhibitors in patients with relapsed and refractory marginal zone lymphoma.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Preface – ASCO/EHA/ICML 2021
As virtual scientific conferences are becoming part of our daily routine as clinicians and researchers, information in individual areas of interest is easily accessible across different congresses.